首页> 外文会议>Meet the Candidates Poster Sessions: 2021 AIChE Annual Meeting"Global challenges for engineering a sustainable future" : November 7-11 (Boston), November 15-19 (Online) : conference proceedings >Transport-driven engineering of liposomes for delivery of a-particle radiotherapy to solid tumors:effect on inhibition of tumor progression and onset delay of spontaneous metastases
【24h】

Transport-driven engineering of liposomes for delivery of a-particle radiotherapy to solid tumors:effect on inhibition of tumor progression and onset delay of spontaneous metastases

机译:脂质体的转运驱动工程化对实体瘤进行 a 粒子放疗:抑制肿瘤进展和延缓自发性转移发生的影响

获取原文
获取原文并翻译 | 示例

摘要

Purpose Highly cytotoxic a-particle radiotherapy delivered by tumor-selective nanocarriers is evaluated on metastatic Triple Negative Breast Cancer(TNBC).On vascularized tumors,the limited penetration of nanocarriers(<50-80 μm)combined with the short range of a-particles(40-100 μm)may,however,result in only partial tumor irradiation,compromising efficacy.Utilizing the a-particle emitter Actinium-225(225Ac),we studied how the therapeutic potential of a general delivery strategy using nanometer-sized engineered liposomes was affected by two key transport-driven properties:(1)the release from liposomes,when in the tumor interstitium,of the highly diffusing 225Ac-DOTA that improves the uniformity of tumor irradiation by a-particles and(2)the adhesion of liposomes on the tumors'ECM that increases liposomes'time-integrated concentrations within tumors and,therefore,the tumor-delivered radioactivities.Methods On an orthotopic MDA-MB-231 TNBC murine model forming spontaneous metastases,we evaluated the maximum tolerated dose(MTD),biodistributions,and control of tumor growth and/or spreading after administration of 225Ac-DOTA-encapsulating liposomes,with different combinations of the two transport-driven properties.Results At 83% of MTD,225Ac-DOTA-encapsulating liposomes with both properties(1)eliminated formation of spontaneous metastases and(2)best inhibited the progression of orthotopic xenografts,compared to liposomes lacking one or both properties.These findings were primarily affected by the extent of uniformity of the intratumoral microdistributions of 225Ac followed by the overall tumor uptake of radioactivity.At the MTD,long-term toxicities were not detected 9.5 months post administration.Conclusion Our findings demonstrate the potential of a general,transport-driven strategy enabling more uniform and prolonged solid tumor irradiation by a-particles without cell-specific targeting.
机译:目的 在转移性三阴性乳腺癌 (TNBC) 上评估肿瘤选择性纳米载体提供的高细胞毒性 a 粒子放疗。在血管化肿瘤中,纳米载体 (<50-80 μm) 的有限穿透性与 a 颗粒的短范围 (40-100 μm) 相结合,可能只导致部分肿瘤照射,影响疗效。利用 a 粒子发射器 Actinium-225(225Ac),我们研究了使用纳米级工程脂质体的一般递送策略的治疗潜力如何受到两个关键运输驱动特性的影响:(1) 当在肿瘤间质中时,脂质体释放高度扩散的 225Ac-DOTA,这提高了 a 粒子照射肿瘤的均匀性和 (2) 脂质体在肿瘤 ECM 上的粘附,增加了脂质体在肿瘤内的时间积分浓度因此,肿瘤递送的放射性。方法 在形成自发性转移的原位 MDA-MB-231 TNBC 小鼠模型上,我们评估了 225Ac-DOTA 包膜脂质体给药后的最大耐受剂量 (MTD) 、生物分布以及肿瘤生长和/或扩散的控制,以及两种运输驱动特性的不同组合。结果 在 83% 的 MTD 中,与缺乏一种或两种特性的脂质体相比,具有两种特性的 225Ac-DOTA 封装脂质体 (1) 消除了自发性转移的形成,并且 (2) 最好地抑制了原位异种移植物的进展。这些发现主要受 225Ac 瘤内微分布均匀程度的影响,其次是肿瘤对放射性的总体摄取。在 MTD 时,给药后 9.5 个月未检测到长期毒性。结论我们的研究结果表明,一种通用的、运输驱动的策略的潜力,可以在没有细胞特异性靶向的情况下通过 a 粒子进行更均匀和持久的实体瘤照射。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号